Among patients with metastatic melanoma, the density of CD8+ T cells at the invasive margin of a tumor was more strongly associated with response to pembrolizumab versus central infiltration (i.e., the density of CD8+ T cells inside the tumor) [67]. The gene discussed is CD8A; the disease is neoplasm.